Informe nº Osteba D12-04. - Euskadi.net

ESTRATEGIAS TERAPÉUTICAS EN LA ESQUIZOFRENIA REFRACTARIA O ESQUIZOFRENIA RESISTENTE AL TRATAMIENTO54. Rosebush PI, Hildebrand AM, Furlong BG, MazurekMF. Catatonicsyndrome in a generalpsychiatric inpatient population: frequency,clinical presentation, and response to lorazepam.J Clin Psychiatry. 1990; 51:357–362.55. Rummel C, Kissling W, Leucht S. Antidepressantsfor the negative symptoms of schizophrenia.[Systematic Review] CochraneSchizophrenia Group Cochrane Database ofSystematic Reviews. 2007; 4.56. Salokangas RK, Saarijarvi S, Taiminen T, KallioniemiH, LehtoH, Niemi H, Tuominen J, AholaV, Syvalahti E. Citalopram as an adjuvant inchronic schizophrenia: a double-blind placebocontrolledstudy. Acta Psychiatr Scand.1996; 94:175–180.57. Schmider J, Standhart H, Deuschle M, DrancoliJ, Heuser I. Adouble-blind comparison oflorazepam and oxazepam in psychomotor retardationand mutism. Biol Psychiatry. 1999;46:437–441.58. Schulz SC, Thompson PA, Jacobs M, Ninan PT,Robinson D, Weiden PJ, Yadalam K, Glick ID,Odbert CL. Lithium augmentation fails to reducesymptoms in poorly responsive schizophrenicoutpatients. J Clin Psychiatry. 1999;60:366–372.59. Schwarz C, Volz A, Li C, Leucht S. Valproato forschizophrenia. Cochrane Database Syst Rev.Jul 16; (3).60. Sepehry AA, Potvin S, Elie R, Stip E. Selectiveserotonin reuptake inhibitor (SSRI) add-ontherapy for the negative symptoms of schizophrenia:a meta-analysis. J. Clin Psychiatry.2007 Apr; 68 (4): 604-10.61. Silver H, Shmugliakov N. Augmentation withfluvoxamine butnot maprotiline improvesnegative symptoms in treatedschizophrenia:evidence for a specific serotonergic effectfroma double-blind study. J Clin Psychopharmacol.1998; 18:208–211.62. Silver H, Barash I, Aharon N, Kaplan A, PoyurovskyM. Fluvoxamine augmentation of antipsychoticsimproves negative symptoms inpsychotic chronic schizophrenic patients: aplacebo-controlled study. Int Clin Psychopharmacol.2000; 15:257–261.63. Silver H, Nassar A, Aharon N, Kaplan A. Theonset and time course of response of negativesymptoms to add-on fluvoxamine treatment.Int Clin Psychopharmacol. 2003;18:87–92.64. Siris SG. Akinesia and postpsychotic depression:a difficult differential diagnosis. J ClinPsychiatry. 1987; 48:240–243.65. Siris SG, Bermanzohn PC, Mason SE, ShuwallMA. Maintenance imipramine therapy for secondarydepression in schizophrenia:a controlledtrial. Arch Gen Psychiatry. 1994;51:109–115.66. Small JG, Kellams JJ, Milstein V, Moore J. A placebo-controlledstudy pf lithium combinedwith neuroleptics in chronic schizophrenicpatients. Am J Psychiatry. 1975; 132: 1.315-7.67. Terao T, Oga T, Nozaki S, Ohta A, Ohtsubo Y,Yamamoto S, Zamami M, Okada M. Lithiumaddition to neuroleptic treatment in chronicschizophrenia: a randomized, double-blind,placebo-controlled, cross-over study. ActaPsychiatr Scand. 1995; 92:220–224.68. Tiihonen J, Halonen P, Wahlbeck K, Repo-TiihonenE, Hyvärinen S, Eronen, Putkonen H,Tácala P, Mehtonen O-P, Puck M, Oksanen J,Koskelainen P, Joffe G, Aer J, Hallikainen T,Ryynänen O-P, Tupala E. Adición de topiramatoen esquizofrenia resistente a tratamiento:ensayo aleatorizado, doble ciego,controlado con placebo y cruzado. J ClinPsychiatry. 2005; 66: 1.012-1.015.69. Tiihonen J, Wahlbeck K, Kiviniemi V. The efficacyof lamotrigine in clozapine-resistantschizophrenia: a systematic review and metaanalysis.Schizophr Res. 2009 Apr; 109(1-3):10-4.70. Tsai G, Yang P, Chung LC, Lange N, Coyle JT. D-Serine added to antipsychotics for the treatmentof schizophrenia. Biol Psychiatry. 1998;44:1.081–1.089.71. Tsai GE, Yang P, Chung LC, Tsai IC, Tsai CW,Coyle JT. D-Serine added to clozapine for the96